Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis

BACKGROUND/AIMS: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy of a new vedolizumab subcutaneous (SC) formulation. METHODS: Eligible patients received open-label...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Taku, Ito, Hiroaki, Ashida, Toshifumi, Yokoyama, Tadashi, Nagahori, Masakazu, Inaba, Tomoki, Shikamura, Mitsuhiro, Yamaguchi, Takayoshi, Hori, Tetsuharu, Pinton, Philippe, Watanabe, Mamoru, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566830/
https://www.ncbi.nlm.nih.gov/pubmed/32806876
http://dx.doi.org/10.5217/ir.2020.00026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566830/
https://www.ncbi.nlm.nih.gov/pubmed/32806876
http://dx.doi.org/10.5217/ir.2020.00026

Ejemplares similares